Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 6/20 | 0.49 |
| ▸ | MME | P08473 | 5/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051563 | 0.91 | CTSC (0.59) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL29695560 | 0.90 | CTSC (0.58) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL6367397 | 0.90 | CTSC (0.56) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL22127884 | 0.90 | CTSC (0.56) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL6367393 | 0.90 | CTSC (0.56) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL30240006 | 0.90 | CTSC (0.48) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL29706522 | 0.89 | MME (0.45) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL29437875 | 0.88 | NTSR2 (0.49) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL31688047 | 0.88 | CTSC (0.51) | CTSCACEMMECPA1ACE2 | |
| SCHEMBL33721998 | 0.87 | CTSC (0.57) | CTSCACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | CTSC 873/4885ACE 277/4885MME 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.